<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087914</url>
  </required_header>
  <id_info>
    <org_study_id>STU00215128</org_study_id>
    <nct_id>NCT05087914</nct_id>
  </id_info>
  <brief_title>Novel Non-opioid Post-surgical Pain Treatment in Females</brief_title>
  <official_title>Novel Non-opioid Post-surgical Pain Treatment in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if treatment with Carbidopa/Levodopa and Naproxen in females&#xD;
      (biological sex) with acute pain after a bunionectomy or toe fusion (24hrs, 48hrs and 5 days)&#xD;
      will reduce pain when compared with females receiving Placebo and Naproxen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute post-surgical pain remains commonly treated with opioids. Although such treatments are&#xD;
      efficacious, they can lead to opioid dependency. Disturbingly, opioid abuse often began as a&#xD;
      direct consequence of prescription medications, primarily for pain management, and&#xD;
      post-surgical pain management. Recent studies in from Apkarian lab suggest that the&#xD;
      combination of dopamine and non-steroidal anti-inflammatory may be a safe, tolerable and&#xD;
      efficacious novel post-surgical pain treatment option.&#xD;
&#xD;
      Therefore, the main hypothesis is: patients treated with Carbidopa/Levodopa and Naproxen will&#xD;
      show a statistically significant decrease in post-surgical pain when compared with control&#xD;
      intervention (Placebo plus Naproxen (250mg)). This will be done through a double-blind,&#xD;
      randomized, placebo-controlled, parallel-group trial of the pharmacological treatment&#xD;
      Carbidopa/Levodopa for females (N = 60) undergoing a bunionectomy or toe fusion surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Surgical Pain using Numeric Rating Scale (NRS)</measure>
    <time_frame>1 and 4 weeks</time_frame>
    <description>The primary endpoint will be the severity of pain measured by mean post surgical pain from surgery to end of intervention (~1 week) and end of the study, as indexed by a NRS. The NRS pain scale is a simple 10- point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine''). Mean pain during treatment will be compared between intervention groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>1 and 4 weeks</time_frame>
    <description>This questionnaire reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. PGIC score will be compared between intervention groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 and 4 weeks</time_frame>
    <description>Participants will be query for possible adverse events during the intervention period (~1 weeks). Incidence of adverse events will be reported every visit.The frequency and severity of adverse effects will be compared between each intervention group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Pain</condition>
  <condition>Bunionectomy</condition>
  <condition>Toe Fusion</condition>
  <arm_group>
    <arm_group_label>Carbidopa-Levodopa (100mg/25mg) + Naproxen (250mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug, Carbidopa-Levodopa, is an FDA-approved medicine traditionally used for the treatment of Parkinson's disease. The study drug will be used for an un-approved or un-labeled use: potentially managing pain in post-surgical patients. Carbidopa/Levodopa is an artificially made version of a naturally occurring hormone that helps regulate brain activity (Levodopa), combined with an artificially made version of a naturally occurring molecule that inhibits the breakdown of Levodopa (Carbidopa).&#xD;
Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Naproxen (250mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo:Participants will receive 1 the capsules on a three-times a day schedule for 5 days. A placebo looks like the study drug but is an inactive substance that has no medication. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.&#xD;
Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa-Levodopa (100mg/25mg):</intervention_name>
    <description>Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.</description>
    <arm_group_label>Carbidopa-Levodopa (100mg/25mg) + Naproxen (250mg)</arm_group_label>
    <other_name>Sinemet</other_name>
    <other_name>Parcopa</other_name>
    <other_name>Rytary</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.</description>
    <arm_group_label>Carbidopa-Levodopa (100mg/25mg) + Naproxen (250mg)</arm_group_label>
    <arm_group_label>Placebo + Naproxen (250mg)</arm_group_label>
    <other_name>Aleve</other_name>
    <other_name>Anaprox</other_name>
    <other_name>Naprosyn</other_name>
    <other_name>Naprelan</other_name>
    <other_name>Menstridol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female with no racial or ethnic restrictions;&#xD;
&#xD;
          -  18 to 75 years old;&#xD;
&#xD;
          -  Have a bunionectomy or toe fusion surgery scheduled;&#xD;
&#xD;
          -  must be able to read, understand, and sign consent form;&#xD;
&#xD;
          -  generally healthy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic neurologic conditions, e.g., Parkinson's&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  opioids use 60 mg/day oral morphine milligram equivalent.;&#xD;
&#xD;
          -  use of anticoagulants (low dose ASA allowed);&#xD;
&#xD;
          -  history of gastric ulcer; renal insufficiency or congestive heart failure,&#xD;
&#xD;
          -  contraindication to study medication as determined by surgeon&#xD;
&#xD;
          -  Any medical condition that in the investigator's judgment may prevent the individual&#xD;
             from completing the study or put the individual at undue risk&#xD;
&#xD;
          -  In the judgment of the investigator, unable or unwilling to follow protocol and&#xD;
             instructions;&#xD;
&#xD;
          -  Diagnosis of psychological diseases, such as major depression; bipolar disorder.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female (biological sex) with no racial or ethnic restrictions</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Camila Bonin Pinto, PhD</last_name>
    <phone>312 503 3971</phone>
    <email>postsurgicalpain@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arash Nadimi, MD</last_name>
    <phone>312 503 3971</phone>
    <email>postsurgicalpain@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pain Studies</last_name>
      <phone>312-503-3971</phone>
      <email>postsurgicalpain@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Apkar Apkarian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camila Pinto, PhD</last_name>
      <phone>312-503-3971</phone>
      <email>postsurgicalpain@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Arash Nadimi, MD</last_name>
      <phone>(312) 975 0594</phone>
      <email>postsurgicalpain@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Apkar Apkarian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoun Nader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Apkar Apkarian</investigator_full_name>
    <investigator_title>Director Center for Translational Pain Research; Director Center of Excellence for Chronic Pain and Drug Abuse Research; Professor of Neuroscience; Anesthesia, and PM&amp;R</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

